An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease

被引：0
|
作者：
Mahmoud Ahmed Ebada
Abdelmagid M. Elmatboly
Ahmed Said Ali
Ahmed Mohamed Ibrahim
Notila Fayed
Ahmed Faisal Faisal
Souad Alkanj
机构：
[1] Zagazig University,Faculty of Medicine
[2] Medical Research Group of Egypt (MRGE),Zagazig University Hospitals
[3] Zagazig University,Faculty of Medicine
[4] Al-Azhar University,undefined
来源：
International Journal of Colorectal Disease | 2019年 / 34卷
关键词：
CT-P13; Infliximab; IFX; Inflammatory bowel diseases; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1633 / 1652
页数：19
相关论文
共 50 条
  • [1] An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
    Ebada, Mahmoud Ahmed
    Elmatboly, Abdelmagid M.
    Ali, Ahmed Said
    Ibrahim, Ahmed Mohamed
    Fayed, Notila
    Faisal, Ahmed Faisal
    Alkanj, Souad
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (10) : 1633 - 1652
  • [2] The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
    Hu, Xinyue
    Tang, Xiaowei
    Li, Limin
    Luo, Lian
    He, Xinsen
    Yan, Qin
    Zhong, Xiaolin
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [3] Infliximab biosimilar CT-P13 for inflammatory bowel disease
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 373 - 375
  • [4] Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
    Jung, Yoon Suk
    Park, Dong Il
    Kim, Young Ho
    Lee, Ji Hyun
    Seo, Pyoung Ju
    Cheon, Jae Hee
    Kang, Hyoun Woo
    Kim, Ji Won
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (12) : 1705 - 1712
  • [5] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [6] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [7] Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis
    Hanzel, J.
    Strik, A.
    Gecse, K.
    D'Haens, G.
    Dreesen, E.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S367 - S368
  • [8] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [9] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13) in patients with inflammatory bowel disease
    María Fernanda Guerra Veloz
    Federico Argüelles-Arias
    Luisa Castro Laria
    Belén Maldonado Pérez
    Antonio Benítez Roldan
    Raúl Perea Amarillo
    Vicente Merino Bohórquez
    Miguel Angel Calleja
    ángel Caunedo álvarez
    ángel Vilches Arenas
    World Journal of Gastroenterology, 2018, (46) : 5288 - 5296
  • [10] Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
    Guerra Veloz, Maria Fernanda
    Arguelles-Arias, Federico
    Castro Laria, Luisa
    Maldonado Perez, Belen
    Benitez Roldan, Antonio
    Perea Amarillo, Raul
    Merino Bohorquez, Vicente
    Angel Calleja, Miguel
    Caunedo Alvarez, Angel
    Vilches Arenas, Angel
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5288 - 5296
12345